β-Blocker therapy for heart failure

Current Opinion in Cardiology

Volumn 11, Issue 3, 1996, Pages 263-268

  Slatton, Monte L ^a   Eichhorn, Eric J ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; METOPROLOL;

ADRENERGIC ACTIVITY; CONGESTIVE HEART FAILURE; EXERCISE TOLERANCE; HEART DILATATION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MORTALITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SURVIVAL RATE;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CELL DIVISION; GENE EXPRESSION; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; MUSCLE FIBERS; SURVIVAL RATE; VASODILATOR AGENTS; VENTRICULAR FUNCTION, LEFT;

EID: 0029890101     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-199605000-00006     Document Type: Review

References (56)

1. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I: Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975, 37:1022-1036.
2. Eichhorn EJ, Heesch CM, Barnett JH, Alvarez LG, Fass SM, Grayburn PA, Hatfield BA, Marcoux LG, Malloy CR: Effect of metoprolol on myocardial function and energetics in patients with non-Ischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 1994, 24:1310-1320. This double-blind, placebo-controlled study demonstrates that metoprolol improves ventricular performance, contractility, and efficiency in patients with dilated cardiomyopathy. This study also suggests a link between adrenergic activation and substrate utilization.
3. Eichhorn EJ, Bedotto JB, Malloy CR, Hatfield B, Deitchman D, Brown M, Willard JE, Grayburn PA: Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure: improvements in hemodynamic, contractile, and diastolic performance with bucindolol. Circulation 1990, 82:473-483.
4. Packer M, Gottlieb SS, Kessler PD: Hormone-electrolyte interactions in the pathogenesis of lethal cardiac arrhythmias in patients with congestive heart failure: basis of a new physiologic approach to control of arrhythmia. Am J Med 1986, 80(suppl 4A):23-29.
5. Vatner SF, Shannon R, Hittinger L: Reduced subendocardial coronary reserve: a potential mechanism for impaired diastolic function in the hypertrophied and failing heart Circulation 1990, 81(suppl 3):III-38-III-14.
6. Weiss MB, Ellis K, Sciacca RR, Johnson LL, Schmidt DH, Cannon PJ: Myocardial blood flow in congestive and hypertrophic cardiomyopathy: relationship to peak wall stress and mean velocity of circumferential fiber shortening. Circulation 1976, 54:484-494.
7. Hasenfuss G, Holubarech C, Heiss HW, Meienertz T, Bonzel T, Wais U, Lehmann M, Just H: Myocardial energetics in patients with dilated cardiomyopathy: influence of nitroprusside and enoximone. Circulation 1989, 80:51-64.
8. Sabbahh HN, Goldstein S: Ventricular remodelling: consequences and therapy. Eur Heart J 1993, 14(suppl C):24-29.
9. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ: Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol 1995, 25:1154-1161. This is the first study to suggest that the pathologic remodeling process in heart failure can be reversed, not just slowed down. This study suggests that left ventricular mass and sphericity changes can be reversed with β-biockade.
10. Packer M, Lee WH, Kessler PD, Gottlieb SS, Bernstein JL, Kukin ML: Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure. Circulation 1987, 75(suppl 4):IV-60-IV-92.
11. Packer M, Carver JR, Chesebro JH, et al.: Effect of mllrinone on mortality in severe chronic heart failure: the Prospective Randomized Milrinone Survival Evaluation (PROMISE). N Engl J Med 1991, 325:1468-1475.
12. The CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987, 316:1429-1435.
13. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293-302.
14. Gilbert EM, Sandoval A, Larrabee P, Renlund DG, O'Connell JB, Bristow MR: Lisinopril lowers cardiac adrenergic drive and increases beta-receptor density in the failing human heart Circulation 1993, 88:472-480.
15. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A, for the V-HeFT VA Cooperative Studies Group: Plasma norepinephrine, plasma renin activity, and congestive heart failure. Circulation 1993, 87(suppl 6):V-I40-V-I48.
16. Katz A: The cardiomyopathy of overload: an unnatural growth response in the hypertrophied heart Ann Intern Med 1994, 121:363-371. An excellent review of the possible role of neurohormonal activation for promoting growth and apoptosis in patients with heart failure.
17. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Hartston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, Goldman S, Cobb FR, Shah PM, Saunders R, Fletcher RD, Loeb HS, Hughes VC, Backer B: Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration cooperative study. N Engl J Med 1986, 314:1547-1552.
18. Califf RM, Adams KF, Armstrong FW, Darius H, Gheorghiade M, Handberg E, Harrell FE, McKenna WJ, McNulty SE, Schulman K, Soler-Soler J, Swedberg K, Uretsky B, Wheeler WS, Zannad F: Flolan International Randomized Survival Trial Study (RRST): final results [abstract]. J Am Coll Cardiol 1996; 27(Suppl A):141A.
19. Barjon JN, Rouleau JL, Bichet D, Juneau C, DeChamplain J: Chronic renal and neurohumoral effects of the calcium entry blocker nisoldipine in patients with congestive heart failure. J Am Coll Cardiol 1987, 9:622-630.
20. Furberg CD, Yusef S: Effects of drug therapy on survival in chronic congestive heart failure. Am J Cardiol 1988, 62:41A-45A.
21. Packer M: Pathophysiological mechanisms underlying the adverse effects of calcium channel-blocking drugs in patients with chronic heart failure. Circulation 1980, 6(suppl 4):IV-59-IV-67.
22. Elkayam U, Amin J, Mehra A, Vasquez J, Weber L, Rahimtoola SH: A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedlplne therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 1990, 82:1954-1961.
23. Calcium antagonist caution [editorial]. Lancet 1991, 337:885-886.
24. Goldstein RE, Boccuzzi SJ, Fruess D, Nattel S, the Adverse Experience Committee, and the Multicenter Diltiazem Postinfarction Research Group: Dilitizem increases late-onset congestive heart failure in post infarction patients with early reduction in ejection fraction. Circulation 1991, 83:52-60.
25. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes CV, Carson P, Cintron G, Shabetai R, Haakenson C: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991, 325:303-310.
26. 1]angiotensin II receptor-mediated stimulation of protein synthesis in chick heart cells. Am J Physiol 1990, 258:H806-H813.
27. Dzau VJ: Local contractile and growth modulators in the myocardium. Clin Cardiol 1993, 16:116-119.
28. Weber KT, Anversa P, Armstrong PW, et al.: Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol 1992, 20:3-16.
29. Lindpaintner K, Ganten D: The cardiac renin-angiotensin system: an appraisal of present experimental and clinical evidence. Circ Res 1991, 66:905-921.
30. Weber KT, Brilla CG: Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991, 83:1849-1865.
31. Tsutsui H, Spinale FG, Nagatus M, Schmid PG, Ishihara K, DeFreyte G, Cooper G, Carabello BA: Effects of chronic β-adrenergic blockade on the left ventricular and cardiocyte abnormalities of chronic canine mitral regurgitation. J Clin Invest 1994, 93:2639-2648.
32. Wisenbaugh T, Katz I, Davis J, Essop R, Skoularigis J, Middlemost S, Rothlisberger C, Skudicky D, Sareli P: Long-term (3 months) effects of a new β-blocker (neblvolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol 1993, 21:1094-1100.
33. The Captopril-Digoxin Multicenter Research Group: Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 1988, 259:539-544.
34. Australia-New Zealand Heart Failure Research Collaborative Group: Effects of carvedilol, a vasodilator-β-blocker, in patients with congestive heart failure due to ischemic heart diaease. Circulation 1995, 92:212-218.
35. Waagstein F, Bristwo MR, Swedberg, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A, for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group: Beneficial effects of metoprolol in idiopathic dilated Cardiomyopathy. Lancet 1993, 342:1441-1446.
36. Bristow MR, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, Orie J, Smucker ML, Marshall G, Kelly P, Deitchman D, Anderson JL, for the Bucindolol Investigators: Dose-response of chronic β-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation 1994, 89:1632-1642.
37. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger R, Kubo SH, Narahara KA, Ingersoll H, for the MOCHA Investigators: Multicenter Oral Carvedilol Heart Failure Assessment (MOCHA): a six-month dose-response evaluation in class II-IV patients [abstract]. Circulation 1995, 92:1142.
38. Woodley SL, Gilbert EM, Anderson JL, O'Connell JB, Deitchman D, Yanowitz FG, Mealey PC, Volkman K, Renlund DG, Bristow MR: β-Blockade with bucindolol in heart failure due to ischemic vs idiopathic dilated cardiomyopathy. Circulation 1991, 84:2426-2441.
39. Neubauer S, Gauchon P, Horn M, Hu K, Tian R, Krahe T: Beta-blockers in cardiac failure. Eur Heart J 1994, 15(suppl C):16-24.
40. Vik-Mo H, Mjos OD: Influence of free fatty acids on myocardial oxygen consumption and ischemic injury. Am J Cardiol 1981, 48:361-365.
41. Kjekshus JK, Mjos OD: Effect of inhibition of lipolysis on myocardial oxygen consumption in the presence of isoproterenol. J Clin Invest 1972, 51:1767-1776.
42. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP: Prognostic implications of echocardiographically determined left ventricular mass in the Famingham Heart Study. N Engl J Med 1990, 322:1561-1566.
43. Quinones MA, Weiner DH, Shelton BJ, Greenberg BH, Limacher MC, Koilpillai C, Shindler DM, Yusuf S, for the SOLVD Investigators: Echocardiographic predictors of one-year clinical outcome in the Study of Left Ventricular Dysfunction (SOLVD) trial and registry: an analysis of 1172 patients [abstract]. Circulation 1993, 88(suppl 1):I-304.
44. Douglas PS, Morrow R, Ioli A, Reichek N: Left ventricular shape, afterload and survival in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1989, 13:311-315.
45. Engelmeier RS, O'Connell JB, Walsh R, Rad N, Scanlon PJ, Gunnar RM: Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated: a double-blind, randomized, placebo-controlled trial. Circulation 1985, 72:536-546.
46. Pollock SG, Lytash J, Tedesco C, Craddock G, Smucker ML: Usefulness of bucindolol in congestive heart failure. Am J Cardiol 1990, 66:603-607.
47. Metra M, D'Aloia A, Panina G, Nardi M, Giubbini R, Dei Cas L: Effects of acute and chronic carvedilol on resting and exercise hemodynamics of patients with idiopathic cardiomyopathy [abstract]. J Am Coll Cardiol 1993, 21 (suppl A):114A.
48. Olsen SL, Gilbert EM, Renlund DG, Mealey PC, Taylor DO, Volkman K, Bristow MR: Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol 1995, 25:1225-1231.
49. Paolisso G, Gambardella A, Marrazzo G, Verza M, Teasuro P, Varricchio M, D'Onofrio F: Metabolic and cardiovascular benefits deriving from β-adrenergic blockade in chronic congestive heart failure. Am Heart J 1992, 123:103-110.
50. Krum H, Sackner-Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J, Medina N, Yushak M, Horn E, Katz SD, Levin HR, Neuberg GW, DeLong G, Packer M: Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995, 92:1499-1506.
51. Ikram H, Fitzpatrick D: Double-blind trial of chronic oral β-blockade in congestive cardiomyopathy. Lancet 1981, ii:490-493.
52. Currie PJ, Kelly KJ, McKenzie: Oral β-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy. J Am Coll Cardiol 1984, 3:203-209.
53. Gilbert EM, Anderson JL, Deitchman D: Long-term β-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med 1990, 88:223-229.
54. CIBIS Investigators and Committees: A randomized trial of beta-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994, 90:1765-1773. This large multicenter trial suggests that β-blockade can result in a mortality benefit, especially in patients with no coronary artery disease, although it was too underpowered to definitively make this conclusion.
55. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH, for the US Carvedilol Heart Failure Study Group: Effect of carvedilol on morbidity and mortality in chronic heart failure. N Engl J Med 1996, in press.
56. Fisher ML, Gottlieb SS, Plotnick GD, Greenberg NL, Patten RD, Bennett SK, Hamilton BP: Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol 1994, 23:943-950.